Search Results

You are looking at 131 - 140 of 1,146 items for :

  • Refine by Access: All x
Clear All
Full access

Michael P. Porter and Paul H. Lange

Vermooten V . Indications for conservative surgery in certain renal tumors: Study based on growth pattern of clear cell carcinoma . J Urol 1950 ; 64 : 200 – 208 . 5 Zinman L Dowd JB . Partial nephrectomy in renal cell carcinoma . Surg Clin

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

Effectiveness Research (CER) and the SEER registry. The CDC-CER registries reabstracted medical records and collected detailed and complete first-course treatment information, including type of surgery, radiation, and all systemic treatments, from all sources

Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

for craniectomies, and each lesion was excised over 2 different surgeries. This was followed by whole brain radiation. Figure 1 Liver metastases (A) pretreatment, (B) post FOLFOX (5-FU, leucovorin, and oxaliplatin) and bevacizumab, and (C) post

Full access

Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong

Background: At our institution, the standard treatment recommendation for esophageal cancer patients with stage IB–IIIB disease is for neoadjuvant chemoradiation per the CROSS regimen prior to surgery. This regimen can be difficult for patients to

Full access

Pamala A. Pawloski, Gabriela Vazquez-Benitez, Jeanette Y. Ziegenfuss, Terese A. DeFor, and Elisabeth M. Seburg

and medical records. Time from diagnosis to surgery, chemotherapy, and radiation was measured in weeks and censored when disenrollment, death, or the end of the study period occurred. We assessed patient factors associated with time to chemotherapy

Full access

David M. Brizel, William Lydiatt, and A. Dimitrios Colevas

clinical equipoise exists with respect to various current and experimental treatment regimens. Surgery has historically been the workhorse of HNC treatment. Over the past 20 years, the treatment of OPC has been largely supplanted by radiation

Full access

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

presentations are found incidentally at surgery for another cause (eg, trauma, appendicitis). Most children present with a solitary tumor in one kidney. However, 5%–13% of children have bilateral tumors and 10% have multifocal tumors in a single kidney. Most

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

older woman. A total of 18 task force members represented medical oncology, radiation oncology, surgical oncology, geriatric oncology, geriatrics, plastic surgery, and patient advocacy. All task force members were identified and invited solely by NCCN. A

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

more effective treatment. 5 Treatment Approach The treatment of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or

Full access

Jaffer A. Ajani, Thomas A. D’Amico, Khaldoun Almhanna, David J. Bentrem, Stephen Besh, Joseph Chao, Prajnan Das, Crystal Denlinger, Paul Fanta, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kory Jasperson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, George A. Poultsides, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese Jr, Mary Kay Washington, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar

complete and most recent version of these guidelines, visit NCCN.org ). Staging The TNM classification developed by the AJCC in 2002 was based on pathologic review of the surgical specimen in patients who underwent surgery as primary therapy. The